6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
Evidence-based guide to pioglitazone (Actos) drug-drug interactions, covering CYP2C8 inhibitors, insulin co-administration, heart failure risk multipliers, and clinical management strategies.
Compare pioglitazone (Actos) pricing against metformin, rosiglitazone, SGLT2 inhibitors, and GLP-1 receptor agonists. Includes mechanism of action, NASH data from PIVENS, and insurance guidance.
How long before surgery should pioglitazone (Actos) be stopped? Board-reviewed guidance on the pre-surgery hold window, fluid-retention risks, anesthetic interactions, and restart protocols.
Stopping pioglitazone (Actos) can trigger glycemic rebound, fluid shifts, NASH relapse, and cardiovascular changes. This MD-level guide covers the mechanisms, timelines, monitoring protocols, and tapering strategies backed by primary literature.
Does pioglitazone protect the kidneys or harm them? This MD/PharmD-level review covers the clinical trial data, mechanisms, contraindications, and prescribing guidance for pioglitazone's renal effects in type 2 diabetes and NASH.
Pioglitazone starts at 15 to 30 mg once daily, titrated every 8 to 12 weeks up to a max of 45 mg based on A1C response and fluid-retention risk.